Development and usability testing of a patient decision aid to enhance shared decision-making regarding treatment decision in type 2 diabetes

The new updated GP guideline opens up the possibility to include DDP4 inhibitors and GLP1-RA in the stepwise treatment for patients with type 2 diabetes. Moreover, SGLT2 inhibitors are now included as a first and second line treatment option. The updated guideline stipulates that the decision for the type of glucose-lowering drug should not only depend on the targeted HbA1c level, but also on the patient’s diabetes-related complications. The values, needs, and preferences of a patient play a more crucial role in providing optimized individualized treatment. This potentially leads to a better patient motivation, adherence and outcomes. Therefore, the aim of the study is to collect and generate patient-preference data specific for type 2 diabetes treatment that can be used for the development of a patient decision aid to support the choice of glucose-lowering drugs.

Neither data on patient preferred attributes specific for type 2 diabetes nor a validated patient decision aid to support healthcare providers is available in the Netherlands. The aim of this study is to collect and generate patient-preference data specific for type 2 diabetes treatment, which can be used for the development of a patient decision aid to support the choice of glucose-lowering drugs.

Phase 1 (01-09-2020 up and till 01-01-2021): focus groups are organized to identify which items – or attributes – patients with type 2 diabetes consider to be important for decision making in type 2 diabetes glucose-lowering drug treatment

Phase 2 (01-01-2021 up and till 01-08-2021): a cross-sectional online best-worst scaling (BWS) object case survey will be developed based on the results of the focus groups. The aim of the survey is to develop a shortlist of 5-15 prioritized patient preferred attributes.

Phase 3 (01-08-2021 up and till 01-02-2022): during this phase several concepts of a decision support tool will be developed. These concepts will be presented to patients with type 2 diabetes and healthcare providers during individual semi-structured interviews. This will lead to the development of a concept PDA for shared decisions making specified for type 2 diabetes.

None